ABU DHABI, United Arab Emirates–(BUSINESS WIRE)–M42, a global health leader powered by artificial intelligence (AI), technology and genomics, and San Diego-based bioinformatics-led company Inocras, have announced a strategic collaboration to advance blood-based monitoring for cancer recurrence in the UAE. Through this partnership, the organizations will deploy Inocras’ MRDVision™ platform—a whole-genome technology suite combining comprehensive genomic profiling with personalized blood assays

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.